Procognia Announced That the Feasibility Stage of the Company's Research in Stem Cells in Cooperation with the Weizmann Institute of Science Has Been Successfully Completed
Published: Mar 22, 2012
TEL-AVIV, Israel--(BUSINESS WIRE)--Procognia (TASE:PRCG) is pleased to announce that the feasibility stage of the research, which focused on the glycosylation structures of stem cells, has been successfully completed. The research, directed by Prof. Dov Zipori from the Weizmann Institute of Science, was designed to develop a platform that will significantly improve the ability to identify and develop unique stem cells for transplant and treatment. Today, stem cell treatment faces a number of challenges, which both parties aim to handle successfully and therefore make a significant contribution to this field.